Twist Bioscience Corporation (NASDAQ:TWST) Stock Has Average Target Price of $143.67 According to Brokerages

Twist Bioscience Corporation (NASDAQ:TWST) has been assigned a consensus rating of “Hold” from the thirteen analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $143.67.

Several research firms have commented on TWST. Guggenheim increased their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Piper Sandler boosted their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Barclays increased their price target on shares of Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Finally, Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a report on Monday, July 6th.

Twist Bioscience Stock Up 5.3%

NASDAQ TWST opened at $139.77 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company has a market capitalization of $8.76 billion, a P/E ratio of -62.96 and a beta of 2.19. Twist Bioscience has a one year low of $23.30 and a one year high of $219.71. The stock has a 50 day moving average price of $148.39 and a 200-day moving average price of $100.92.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same period last year, the business posted $0.33 earnings per share. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, equities analysts predict that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,462 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $156.30, for a total transaction of $384,810.60. Following the sale, the chief financial officer directly owned 98,114 shares in the company, valued at $15,335,218.20. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 4,548 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $202.15, for a total value of $919,378.20. Following the completion of the sale, the chief executive officer directly owned 562,760 shares of the company’s stock, valued at $113,761,934. The trade was a 0.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 601,920 shares of company stock valued at $93,768,202. Corporate insiders own 3.08% of the company’s stock.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Abel Hall LLC lifted its position in Twist Bioscience by 3.6% in the third quarter. Abel Hall LLC now owns 5,514 shares of the company’s stock worth $1,066,000 after buying an additional 191 shares during the last quarter. SteelPeak Wealth LLC increased its position in Twist Bioscience by 8.2% during the third quarter. SteelPeak Wealth LLC now owns 6,143 shares of the company’s stock valued at $1,187,000 after acquiring an additional 466 shares during the last quarter. Triasima Portfolio Management inc. bought a new position in Twist Bioscience during the third quarter valued at $652,000. Sivik Global Healthcare LLC bought a new position in Twist Bioscience during the third quarter valued at $218,000. Finally, Fermata Advisors LLC purchased a new stake in shares of Twist Bioscience in the third quarter valued at $243,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.